Management of antibody mediated rejection in adult renal transplant patients
For ABO blood group and HLA antibody incompatible renal transplantation Use in accordance with local guidelines at GSTFT
Biosimilar products available, to be prescribed by brand name. Contact pharmacy department for advice on brand for routine prescribing if unsure
For human leukocyte antigen antibody incompatible renal transplantation
In high risk recipients who have previously exhibited significant donor specific antibody but are presently negative by flow cytometry crossmatch Use in accordance with local guideline at GSTFT
First Choice item
Section Title (top level)
Non Formulary section
Section Title (sub level)
High Cost Medicine
Link to SPCs
Link to adult BNF
Display tracking information
Cancer Drugs Fund
Traffic Light Status Information
Specialist Prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
Treatment can be initiated in primary care after a recommendation from an appropriate specialist
Specialist initiation followed by maintenance prescribing in primary care
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation